Surotomycin was an investigational oral antibiotic.

This macrolide antibiotic was under investigation by Merck & Co (who acquired Cubist Pharmaceuticals) for the treatment of life-threatening diarrhea, commonly caused by the bacterium Clostridioides difficile.

[1] After reaching phase III in clinical trials, its production was discontinued in 2017 due to its non-superiority to current therapies.

This systemic antibiotic-related article is a stub.

You can help Wikipedia by expanding it.